Suppr超能文献

前列腺切除术后并发应激性尿失禁,用度洛西汀治疗。

Postprostatectomy established stress urinary incontinence treated with duloxetine.

机构信息

Urology Service, Instituto Valenciano de Oncología, Valencia, Spain.

出版信息

Urology. 2011 Aug;78(2):261-6. doi: 10.1016/j.urology.2011.03.006. Epub 2011 May 23.

Abstract

OBJECTIVES

To evaluate the efficacy of duloxetine to treat stress urinary incontinence, 1 of the most frequent complications after radical prostatectomy. Conservative measures and surgery are well-established treatments. However, drug treatment could be an intermediate option.

METHODS

All patients had >1 year of follow-up after radical prostatectomy to avoid interfering with the natural recovery period (established stress urinary incontinence). Continence was measured by the average daily use of pads and the International Consultation on Incontinence Questionnaire-short form. In Spain, it is necessary to proceed with off-label use formality, and all patients were informed and agreed. The initial dose of duloxetine was 30 mg once daily and was increased to 60 mg/d. Drug treatment was maintained for 9 months.

RESULTS

From June 2006 to July 2007, 68 patients were included. The median age was 68 years (range 52-79). The median duration of duloxetine treatment was 5.56 months (range 1-18). A statistically significant decrease in the International Consultation on Incontinence Questionnaire-Urinary Incontinence-short form (from 13 to 9; P < .001) and the average number of pads/d (from 2 to 1; P < .001) was observed between the initial and 3-month visit. At the end of the follow-up period, 74% and 57% of the patients had a reduced International Consultation on Incontinence Questionnaire-Urinary Incontinence-short form score and a decrease in the number of pads used daily, respectively. Of the 68 patients, 32 (47%) presented with some side effects and 17 patients stopped the treatment because of adverse effects (25%).

CONCLUSIONS

Our results suggest that duloxetine is a possible alternative treatment of postprostatectomy established stress urinary incontinence. The continence improvement results were mild and conditioned in part by the frequency of the side effects. Provided that duloxetine does not preclude later continence surgery and the benefits are observed at the first visit, we believe it can be a treatment option for selected patients.

摘要

目的

评估度洛西汀治疗压力性尿失禁(根治性前列腺切除术后最常见的并发症之一)的疗效。保守治疗和手术是既定的治疗方法。然而,药物治疗可能是一种中间选择。

方法

所有患者在根治性前列腺切除术后均有 >1 年的随访,以避免影响自然恢复期(已确立的压力性尿失禁)。通过平均每日使用尿垫的数量和国际尿失禁咨询问卷 - 简短形式来衡量尿失禁。在西班牙,必须进行标签外使用手续,所有患者均被告知并同意。度洛西汀的初始剂量为 30 mg,每日 1 次,并增加至 60 mg/d。药物治疗持续 9 个月。

结果

2006 年 6 月至 2007 年 7 月,共纳入 68 例患者。中位年龄为 68 岁(范围为 52-79 岁)。度洛西汀治疗的中位时间为 5.56 个月(范围为 1-18 个月)。在初始访视和 3 个月访视之间,国际尿失禁咨询问卷 - 尿失禁简短形式(从 13 降至 9;P <.001)和每日尿垫使用量(从 2 降至 1;P <.001)均有统计学显著下降。在随访结束时,74%和 57%的患者国际尿失禁咨询问卷 - 尿失禁简短形式评分降低和每日尿垫使用量减少。在 68 例患者中,32 例(47%)出现了一些副作用,17 例患者因不良反应而停止治疗(25%)。

结论

我们的结果表明,度洛西汀可能是根治性前列腺切除术后已确立的压力性尿失禁的一种替代治疗方法。尿失禁改善的结果是轻微的,部分取决于副作用的频率。鉴于度洛西汀不会排除以后的尿失禁手术,并且在第一次就诊时就观察到了益处,我们认为它可以成为选定患者的治疗选择。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验